Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price

Lantern Pharma

14/08/2026 12:44

Overview
US oncology drug developer's Q2 loss from operations fell about 25% yr/yr
Net loss widened on non-cash warrant expenses tied to higher stock price
Company established Open Medicine AI as a separate subsidiary with commercial licenses

Outlook
Company intends to pursue additional capital raises, collaborations and other opportunities to extend operating runway
Lantern plans to initiate a Phase 1b/2 trial of LP-184 in triple-negative breast cancer
Open Medicine AI intends to raise capital and may seek a future public listing

Result Drivers
LOWER R&D SPENDING - Co said reduced research studies and materials expenses led to lower loss from operations
AI SUBSIDIARY LAUNCH - Establishment of Open Medicine AI as a separate company with board-approved commercial licenses
CLINICAL TRIAL PROGRESS - Protocol amendments and emerging data in LP-300 HARMONIC trial focused on EGFR exon 21 L858R lung cancer subgroup

Company press release: ID:nBwbxcClha

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.57
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Lantern Pharma Inc is $17.50, about 565.4% above its August 13 closing price of $2.63

Reuters Recommended Reads
Aug 11 - Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise
Aug 13 - Aktis Oncology Q2 net loss widens on higher R&D, administrative costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)